Taho Pharmaceuticals Ltd. (TPEX:6467)
Taiwan · Delayed Price · Currency is TWD 144.00
+5.50 (3.97%)
At close: Jan 19, 2026
Taho Pharmaceuticals Company Description
Taho Pharmaceuticals Ltd., a pharmaceutical company, develops products using transdermal and transmucosal systems in Taiwan.
Its pipeline includes TAH4411 Ondansetron ODF, a selective serotonin 5HT3 receptor antagonist for the treatment of chemotherapy-induced nausea and vomiting; and TAH3311 Apixaban oral film and TAH3341 Apixaban oral extend release films for patients with Dysphagia.
The company also develops TAH2211 Buprenorphine/Naloxone sublingual film and TAH2231 Naloxone Buccal film for Opioid overdose; TAH9922 Atomoxetine oral liquid and TAH9901 Methylphenidate patch for ADHD treatment.
Taho Pharmaceuticals Ltd. was founded in 2010 and is based in Taipei, Taiwan.
Taho Pharmaceuticals Ltd.
| Country | Taiwan |
| Founded | 2010 |
| Industry | Pharmaceutical Preparations |
| Employees | 27 |
| CEO | Shiren S. Lee |
Contact Details
Address: No.550, Ruiguang Road Taipei, 11492 Taiwan | |
| Phone | 886 2 2659 8515 |
| Website | tahopharma.com |
Stock Details
| Ticker Symbol | 6467 |
| Exchange | Taipei Exchange |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | TWD |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Shiren S. Lee | Chief Executive Officer |
| Yu Zhang | Chief Financial Officer |